Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
 |
UNAIDS Press Release - November 30, 2006
UNAIDS congratulates the Clinton Foundation, pharmaceutical companies Cipla and Rambaxy and the international drug purchase facility UNITAID for their combined action to help provide more children with much needed pediatric treatment.
The new negotiations between the partners will see Indian pharmaceutical companies Cipla and Ranbaxy produce a 'three-in-one' dispersible antiretroviral tablet for less than $60 per child per year. The agreements also mean lower prices for 19 pediatric formulations by 45% for 62 Countries and a $50 million effort lead by the Clinton Foundation with UNITAID to assist 40 countries to expand treatment to 100,000 additional children in 2007.
"This is an example of exceptional innovative partnership and concrete action that is going to make a significant difference to millions of children living with HIV," said UNAIDS Executive Director Dr Peter Piot. "Developments in antiretroviral treatment for children have so far been sorely lacking in the AIDS response." he said.
###
Contact
Beth Magne-Watts | UNAIDS Geneva | +41 22 791 5074 | magnewattsb@unaids.org
061130
UN061108
Copyright © 2006 - Joint United Nations Programme on HIV/AIDS (UNAIDS). All rights reserved. UNAIDS articles, which are not formal publications of UNAIDS, may be freely reviewed, quoted, reproduced or translated, in part or in full, provided the source is acknowledged. The documents may not be sold or used in conjunction with commercial purposes without prior written approval from UNAIDS (contact: UNAIDS Information Centre).
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .